Stanford, CA – April 24, 2024 – In a discovery poised to fundamentally reshape our understanding and treatment of cancer, scientists have uncovered a startling new function for a protein long associated with red blood cell production. Erythropoietin (EPO), identified nearly four decades ago for its crucial role in stimulating erythropoiesis, has now been revealed as a critical modulator of the immune system’s response to cancer, acting as a potent dampener of anti-tumor immunity.
This groundbreaking research, led by Dr. Edgar Engleman of Stanford Medicine, demonstrates that blocking EPO’s activity can transform notoriously "cold," or immune-resistant, liver tumors in mice into "hot" tumors, teeming with cancer-fighting immune cells. When this intervention was combined with an existing immunotherapy designed to further activate these immune cells, the results were nothing short of remarkable: existing liver tumors completely regressed in the majority of treated mice, which subsequently lived for the entire duration of the experiment. In stark contrast, control animals succumbed to their disease within a matter of weeks.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," exclaimed Dr. Engleman, a distinguished professor of pathology and medicine and the senior author of the study. His excitement is palpable, underscoring the profound implications of this finding. "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials."
The pivotal findings are published online today in the prestigious journal Science. Dr. David Kung-Chun Chiu, a basic life research scientist at Stanford, is credited as the lead author of this meticulously executed study, which promises to unlock new avenues for treating a wide array of human cancers that currently evade the most advanced immunotherapies.
The potential reach of this discovery extends far beyond liver cancer. There are compelling indications that EPO plays a similar immunosuppressive role across numerous types of human malignancies, including those of the kidney, breast, colon, and skin. This broad applicability injects immense hope into the fight against cancers that have historically proven resistant to immune-based treatments.
Unraveling EPO’s Dual Nature: From Red Blood Cell Booster to Immune Suppressor
The journey to this revelation is a testament to persistent scientific inquiry, spanning decades and challenging deeply ingrained assumptions about a well-understood biological molecule. For years, EPO has been celebrated for its life-sustaining role in regulating red blood cell production, a function critical for oxygen transport throughout the body. Its therapeutic use has been instrumental in treating anemia, particularly in patients with kidney disease or those undergoing chemotherapy. However, a troubling side to EPO’s seemingly benign nature began to emerge in the early 21st century.
The Early Years: EPO’s Established Role and Unexpected Complications
Nearly 40 years ago, erythropoietin was identified as the primary hormone responsible for stimulating the production of red blood cells. Its mechanism, involving binding to specific receptors on progenitor cells in the bone marrow, was well-characterized. This clear understanding led to the development of recombinant human EPO as a therapeutic agent, offering a lifeline to patients suffering from anemia. For cancer patients undergoing arduous chemotherapy regimens that often suppress bone marrow activity and lead to severe anemia, EPO administration became a standard supportive care measure, aimed at improving their quality of life and avoiding blood transfusions.
The Alarming Connection: A Black Box Warning and a Lingering Mystery
However, the widespread use of EPO in cancer patients started to reveal an alarming, counterintuitive effect. Research conducted more than a decade ago began to show a disturbing correlation: giving EPO to anemic cancer patients to boost red blood cell formation inadvertently accelerated tumor growth. This connection was so striking and concerning that in 2007, the U.S. Food and Drug Administration (FDA) mandated a black box warning label on the drug, cautioning against its use in people with certain cancers due to the risk of tumor progression and shortened survival.
Simultaneously, researchers observed a clear and consistent correlation between a patient’s prognosis and the levels of naturally occurring EPO and its receptor (EPOR) within their tumors. "Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Dr. Engleman recounted. This accumulating evidence pointed to EPO not merely as a growth factor for red blood cells, but as a potential accomplice in cancer progression. Yet, the precise mechanism by which EPO exerted this detrimental effect remained elusive, a significant missing piece in the complex puzzle of cancer biology.
The Current Breakthrough: Connecting the Dots to Immune Evasion
The critical missing link—the connection between EPO and cancer immunity—was never made until now. For years, the scientific community, including Dr. Engleman himself, struggled to reconcile EPO’s known role with its observed impact on cancer. "In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor," Dr. Engleman explained. This historical context highlights the profound challenge of overturning established scientific paradigms and the meticulous research required to do so. The Stanford team’s breakthrough has finally bridged this explanatory gap, revealing EPO as a sophisticated orchestrator of immune suppression within the tumor microenvironment.
The Scientific Foundation: Mouse Models and Mechanistic Insights
The journey to this discovery involved rigorous experimentation, sophisticated modeling, and a deep dive into the molecular intricacies of the tumor microenvironment. Dr. David Kung-Chun Chiu, the lead author, spearheaded the development of advanced experimental platforms that were crucial for unraveling EPO’s complex role.
Methodology: Crafting Precise Cancer Models
Dr. Chiu’s ingenuity was central to the research’s success. He meticulously developed and utilized cutting-edge genome editing techniques to create several distinct mouse models of liver cancer. These models were not generic representations but rather sophisticated recapitulations of specific mutations, histological features, and responses to approved therapies observed in various subtypes of human liver cancers. This precision allowed the researchers to investigate how different genetic drivers influenced tumor development and, crucially, how they responded to therapeutic interventions. Tumor formation was induced using two primary methods: either by injecting a combination of DNA encoding proteins known to be associated with liver cancer into the animals’ tail vein, or by directly implanting liver cancer cells into the animals’ livers. This dual approach ensured robustness and relevance to different clinical scenarios.
The Immunotherapy Challenge: Understanding Cold vs. Hot Tumors
A primary focus of the researchers was to understand the effect of a common and highly effective type of immunotherapy that targets a molecule called PD-1. PD-1 is found on the surface of immune cells known as T cells. When cancer cells bind to PD-1, they effectively put the brakes on T cell activity, allowing the tumor to evade immune destruction. Anti-PD-1 therapies, such as the commercially available Keytruda, work by blocking this interaction, thereby unleashing the T cells to attack the cancer. These therapies have revolutionized the treatment of many human cancers, including melanoma, Hodgkin’s lymphoma, and certain types of lung cancer, transforming patient outcomes from grim prognoses to long-term remission in some cases.
However, a significant limitation of anti-PD-1 therapy is its ineffectiveness against a large majority of tumors. Many cancers, including most liver, pancreas, colon, breast, and prostate cancers, are notoriously resistant to this treatment. These tumors are often characterized as "cold" or "immune privileged" because they lack a substantial infiltration of T cells, rendering the anti-PD-1 mechanism largely irrelevant.
The Stanford team observed similar patterns in their mouse models. Consistent with observations in human liver cancers, some combinations of mutations led to the development of liver tumors that were largely ignored by the immune system – these were the "cold" tumors. These tumors did not shrink when the animals were treated with anti-PD-1 because there were simply too few T cells present within the tumor microenvironment to mount an effective attack.
In stark contrast, other genetic mutations resulted in "hot" or "inflamed" tumors, which were replete with an active population of T cells. These "hot" tumors were highly sensitive to anti-PD-1 treatment, which successfully triggered the T cells to attack and destroy the cancerous cells. This distinction between "cold" and "hot" tumors became a critical backdrop for their unexpected discovery.
The EPO-Hypoxia Link: A Surprising Observation
It was within this context that the researchers made a pivotal, unexpected observation: the "cold" tumors consistently displayed elevated levels of EPO when compared with their "hot" counterparts. This increase was not random but appeared to be a direct consequence of the oxygen-poor microenvironment—a condition known as hypoxia—prevalent in these cold tumors. Hypoxia is a common feature of rapidly growing tumors, as their demand for oxygen outstrips the blood supply. In response to this low oxygen stress, cancer cells induce the production of various proteins, which, in turn, ramp up the production of EPO. The conventional understanding was that this increased EPO production was solely aimed at creating more red blood cells to combat the local low oxygen levels, a physiological response to maintain tissue oxygenation.
"Hypoxia in tumors has been studied for decades," Dr. Engleman noted. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This statement highlights the entrenched scientific dogma that the team had to challenge.
Empirical Validation: Manipulating EPO and Observing the Transformation
Curiosity piqued, the researchers expanded their investigation. They first turned to existing public databases to confirm if elevated levels of EPO were indeed correlated with poorer survival in human patients across various cancer types, including those of the liver, kidney, breast, colon, and skin. The data unequivocally supported this correlation, reinforcing the clinical relevance of their mouse model observations.
The next step involved directly manipulating EPO production within the mouse tumors. The results were nothing short of astonishing. They found that mutations that had previously led to the development of "cold" tumors instead caused "hot" tumors when the tumor cells were genetically modified to be unable to produce EPO. Conversely, "hot" tumors that had previously been successfully eradicated by the immune system thrived and grew unchecked when they were engineered to produce elevated levels of EPO. These experiments provided compelling evidence that EPO was not merely correlated with immune resistance, but was actively causing it.
The Molecular Mechanism: EPO’s Immunosuppressive Pathway
Further exhaustive research painstakingly elucidated the precise molecular mechanism behind EPO’s immunosuppressive role. In "cold" tumors, the cancer cells themselves synthesize and secrete EPO. This secreted EPO then travels through the tumor microenvironment and binds to specific receptors (EPOR) located on the surface of another critical type of immune cell: macrophages.
Macrophages are versatile immune cells that can adopt different roles. When EPO binds to their receptors, it triggers a dramatic shift in their behavior. The macrophages are reprogrammed to adopt an immunosuppressive phenotype. In this state, they actively "shoo away" or inhibit the infiltration and activity of cancer-killing T cells. They create an environment that is hostile to anti-tumor immunity, effectively creating an immune desert around the tumor, allowing it to grow unchecked. This intricate "crosstalk" between tumor cells and macrophages, mediated by EPO, emerged as the central axis of immune evasion.
Synergistic Treatment Outcomes: A Powerful Combination
The importance of this EPO-moderated crosstalk between tumor cells and macrophages was most vividly demonstrated when the researchers studied the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. These experiments provided the definitive proof of concept for a new therapeutic strategy.
In control groups, where mice with "cold" liver tumors were either left untreated or received only anti-PD-1, none lived beyond eight weeks after tumor induction. This stark outcome underscored the inherent resistance of these tumors to conventional immunotherapy.
In contrast, when the researchers engineered the macrophages in mice to be unable to make the EPO receptor—effectively blocking EPO signaling to these immune cells—a remarkable improvement in survival was observed. Forty percent of these mice lived for 18 weeks after tumor induction, at which point the experiment was terminated. This indicated a significant, albeit partial, restoration of anti-tumor immunity.
The truly transformative results, however, came with the combined therapy. When anti-PD-1 treatment was administered to mice whose macrophages lacked the EPO receptor, the outcome was unprecedented: all animals lived for the duration of the experiment, achieving complete and sustained tumor regression.
"It’s simple," Dr. Engleman concluded with conviction. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This statement encapsulates the profound potential of targeting EPO as a strategy to overcome immunotherapy resistance.
Expert Perspectives and Future Trajectories
The implications of this discovery are vast, resonating through the scientific community and offering renewed hope to patients battling difficult-to-treat cancers. Dr. Engleman’s enthusiasm is a powerful indicator of the breakthrough’s significance. His long career at the forefront of immunology and cancer research lends considerable weight to his assessment.
"I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials," Dr. Engleman reiterated, emphasizing the urgency of translating this fundamental insight into clinical benefit. This sentiment is echoed by many in the field who recognize the critical need for novel approaches to combat the large proportion of tumors that currently do not respond to existing immunotherapies.
The research not only identifies a new target but also provides a deeper, more nuanced understanding of how the immune system is regulated within the complex tumor microenvironment. It clarifies why EPO, a molecule primarily known for one vital physiological function, also possessed this detrimental capacity in the context of cancer. The historical data from over a decade ago, which showed that EPO could accelerate tumor growth, now makes complete sense through the lens of immune suppression. The connection was always there, waiting to be unveiled.
The broad applicability of this work is another source of optimism. Given the consistent correlation between elevated EPO/EPOR levels and poor prognosis observed across numerous human cancer types, the therapeutic strategy of targeting EPO signaling is likely not limited to liver cancer but could be effective in kidney, breast, colon, and skin cancers, among others. This represents a significant expansion of potential treatment options for a large patient population currently facing limited therapeutic avenues.
Paving the Way for Novel Therapies: Challenges and Opportunities
The immediate focus following this groundbreaking publication is on translating these findings into effective human treatments. The Stanford team, along with collaborators, is already actively designing strategies to target EPO signaling in human cancers, navigating both the opportunities and the inherent challenges.
Therapeutic Strategies: Balancing Efficacy and Side Effects
Two primary therapeutic strategies are being explored:
-
Non-specific EPO targeting: This approach would involve lowering overall EPO levels or broadly blocking EPO’s activity. While potentially highly effective in turning "cold" tumors "hot," this strategy carries a known side effect: anemia, given EPO’s essential role in red blood cell production. However, Dr. Engleman speculates that for patients facing aggressive, otherwise untreatable cancers, anemia might be an acceptable trade-off for an effective cancer therapy. The potential for life extension or even cure could outweigh the need for supportive care for anemia.
-
Selective blockade of EPO receptors on macrophages: This more targeted approach aims to specifically interfere with EPO’s interaction with immunosuppressive macrophages, leaving EPO’s red blood cell stimulating functions largely intact. By selectively blocking the EPO receptors on the surfaces of these immune cells within the tumor microenvironment, researchers hope to disarm the immunosuppressive machinery without causing systemic anemia. This strategy offers the promise of a more precise intervention with a potentially more favorable side effect profile.
Broader Impact and Collaborative Efforts
This discovery has the potential to unlock entirely new pathways for treating a wide spectrum of immunotherapy-resistant cancers. For patients suffering from liver, pancreas, colon, breast, and prostate cancers—tumors that have largely remained impervious to the transformative effects of anti-PD-1 therapies—this research offers a beacon of hope. By rendering these "cold" tumors "hot," the EPO-targeting strategy could make these currently resistant cancers responsive to existing immunotherapies, thereby dramatically expanding the reach and efficacy of current treatment paradigms.
The research itself was a collaborative endeavor, benefiting from the expertise of researchers from the New York Blood Center and the pharmaceutical company ImmunEdge Inc., highlighting the importance of inter-institutional and industry partnerships in accelerating scientific progress. The study was generously funded by multiple grants from the National Institutes of Health (R01CA262361, P01CA244114, U54CA2745115, and P01HL149626), underscoring the vital role of public funding in supporting high-risk, high-reward basic science.
It is also important to note the translational drive behind this research. Dr. Chiu is a cofounder of ImmunEdge Inc., and Dr. Engleman is a founder, shareholder, and board member of the same company. Both researchers are Stanford-affiliated inventors of a patent application (PCT/US2023/063997), entitled "EPO receptor agonists and antagonists." This direct involvement in commercializing the discovery demonstrates a clear commitment to moving this research from the lab bench to the patient bedside, ensuring that the scientific breakthrough can rapidly translate into tangible therapeutic options.
"I continue to be amazed by this finding," Dr. Engleman concluded, reflecting on the journey. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies." This optimism, grounded in rigorous scientific evidence and a deep understanding of cancer biology, signals a new era in the fight against cancer, where a decades-old protein, once seen primarily as a helper, is now unmasked as a critical vulnerability to be exploited in the quest for effective cures.
About the Author
